Instalab
logoInstalab

Is Jaypirca now a first-line pill for CLL and SLL?

Pirtobrutinib (Jaypirca) is now approved as a first-line daily pill for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as long as the cancer doesn't carry a 17p chromosome deletion. The FDA cleared it on October 2, 2026. The trial behind the approval showed striking disease control versus chemotherapy, and a separate head-to-head against ibrutinib found it at least as effective and easier on the heart. But no trial has yet tested it against the two second-generation BTK pills most oncologists now reach for first.

Is Jaypirca now a first-line pill for CLL and SLL?

The approval covers adults with newly diagnosed CLL or SLL whose cancer doesn't carry a 17p deletion, a chromosomal change seen in roughly 5 to 8% of new diagnoses. The dose is 200 mg once a day, continued until the disease progresses or the drug stops being tolerated. Pirtobrutinib binds its target, Bruton tyrosine kinase (BTK), reversibly, so it keeps working when the cancer picks up the C481 mutation that disables ibrutinib, acalabrutinib, and zanubrutinib. That design is why it was originally cleared for patients who had already failed one of them.

What the approval trial showed

The approval rests on BRUIN CLL-313, a 282-patient randomized trial pitting pirtobrutinib against bendamustine plus rituximab, a standard chemotherapy regimen. The drug cut the risk of progression or death by about four-fifths. The benefit held in the subgroups that usually fare worst with chemotherapy: unmutated IGHV, complex karyotype, and TP53 mutations. If you've been quoted a grim prognosis because of one of those features, this is the trial to look at.

How it compares with the other BTK pills

The harder question is how pirtobrutinib stacks up against ibrutinib, acalabrutinib, and zanubrutinib, the three BTK inhibitors already used in frontline CLL. Only one of those comparisons has been run as a randomized trial. In BRUIN CLL-314, pirtobrutinib was tested head-to-head against ibrutinib in untreated patients. Early progression-free survival favored pirtobrutinib, and rates of atrial fibrillation and high blood pressure were both lower. There's no head-to-head yet against acalabrutinib or zanubrutinib, which have already been shown to be safer than ibrutinib. Indirect network comparisons hint pirtobrutinib may be at least as effective, but the ranges overlap too much to call a winner.

DrugHow it binds BTKFirst-line trial evidenceAtrial fibrillation signal
Pirtobrutinib (Jaypirca)Reversible, non-covalentBeat chemotherapy (BRUIN CLL-313); higher response rate than ibrutinib (BRUIN CLL-314)Low; roughly 2 to 3% in trials
Ibrutinib (Imbruvica)Irreversible; attaches to C481Approved after beating chemotherapy in older trialsHighest; roughly 13 to 16% in head-to-head trials
Acalabrutinib (Calquence)Irreversible; attaches to C481Approved for frontline CLLLower than ibrutinib
Zanubrutinib (Brukinsa)Irreversible; attaches to C481Approved for frontline CLLLower than ibrutinib

Who the new label leaves out, and what else to weigh

The frontline indication specifically excludes anyone with a known 17p deletion. That's the small, highest-risk slice of newly diagnosed CLL, and the trial did not test pirtobrutinib there. If a 17p deletion shows up on your FISH panel, acalabrutinib, zanubrutinib, or a venetoclax-based regimen are the better-studied options; it's worth confirming your FISH and TP53 status before choosing a frontline drug, since both carry weight here.

Side effects in BRUIN CLL-313 were common but mostly manageable: upper respiratory infections in about 27% of patients, rash in 22%, COVID-19 in 21%. Serious adverse events of any kind happened in 28%. Label warnings include infections, bleeding, low blood counts, cardiac arrhythmias, second cancers, and liver injury. The cardiac signal is low compared with ibrutinib, but the drug isn't a free pass; cytopenias and infection risk still warrant monitoring over time.

The sticker price and what you'll likely pay

Lilly's patient assistance foundation can provide the drug at no cost to uninsured or underinsured patients who qualify. Medicare beneficiaries can't use the manufacturer's copay card under federal rules, but foundation grants and patient assistance programs still apply. It's worth running the numbers for your own coverage before you assume the drug is out of reach.

How to think about this news

Pirtobrutinib's move to the front line is a step forward for most newly diagnosed CLL and SLL. It gives stronger disease control than chemotherapy and less heart toxicity than first-generation ibrutinib, and it's taken as a daily pill. Because no trial has yet pitted it against acalabrutinib or zanubrutinib, for now it's one of several first-line options alongside them. A randomized trial of pirtobrutinib against one of those second-generation covalent inhibitors would settle that comparison, and mature overall survival data from the trials now in follow-up, along with a label expansion that includes patients with a 17p deletion, would change who it suits.

Not sure where to start?

Answer a few questions about your health and we'll build you a Game Plan: the tests and screenings worth getting, plus the medications, supplements and lifestyle changes that could help.

2-min assessment · No commitment · HIPAA-compliant